Tags

Type your tag names separated by a space and hit enter

Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis 1988; 137(5):1147-50AR

Abstract

In a study in Singapore, patients of Chinese, Malay, and Indian ethnic origin with sputum-smear-positive pulmonary tuberculosis were allocated at random to daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ), for 1 month (1SHRZ), or for 2 months without streptomycin (2HRZ), followed, for all patients, by 3-times-weekly isoniazid and rifampin (H3 R3) up to 6 months. As previously reported, all except 1 of 319 patients with drug-susceptible tubercle bacilli pretreatment had a favorable bacteriologic status at the end of chemotherapy, and among the 300 patients assessed up to 30 months (24 months after the end of chemotherapy), there was only 1 bacteriologic relapse in each series, giving an overall therapeutic failure rate of only 1.3%. Follow-up has been continued at 6-month intervals up to 5 yr. During the 5 yr, the total relapse rate for patients with drug-susceptible strains pretreatment was 2.4% of 297 patients (95% confidence limits, 1.0 to 4.8%). Among the 31 patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment, there were no failures during chemotherapy and 4 (13%) subsequent relapses.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2904237

Citation

"Five-year Follow-up of a Clinical Trial of Three 6-month Regimens of Chemotherapy Given Intermittently in the Continuation Phase in the Treatment of Pulmonary Tuberculosis. Singapore Tuberculosis Service/British Medical Research Council." The American Review of Respiratory Disease, vol. 137, no. 5, 1988, pp. 1147-50.
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1988;137(5):1147-50.
(1988). Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. The American Review of Respiratory Disease, 137(5), pp. 1147-50.
Five-year Follow-up of a Clinical Trial of Three 6-month Regimens of Chemotherapy Given Intermittently in the Continuation Phase in the Treatment of Pulmonary Tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1988;137(5):1147-50. PubMed PMID: 2904237.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. PY - 1988/5/1/pubmed PY - 1988/5/1/medline PY - 1988/5/1/entrez SP - 1147 EP - 50 JF - The American review of respiratory disease JO - Am. Rev. Respir. Dis. VL - 137 IS - 5 N2 - In a study in Singapore, patients of Chinese, Malay, and Indian ethnic origin with sputum-smear-positive pulmonary tuberculosis were allocated at random to daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ), for 1 month (1SHRZ), or for 2 months without streptomycin (2HRZ), followed, for all patients, by 3-times-weekly isoniazid and rifampin (H3 R3) up to 6 months. As previously reported, all except 1 of 319 patients with drug-susceptible tubercle bacilli pretreatment had a favorable bacteriologic status at the end of chemotherapy, and among the 300 patients assessed up to 30 months (24 months after the end of chemotherapy), there was only 1 bacteriologic relapse in each series, giving an overall therapeutic failure rate of only 1.3%. Follow-up has been continued at 6-month intervals up to 5 yr. During the 5 yr, the total relapse rate for patients with drug-susceptible strains pretreatment was 2.4% of 297 patients (95% confidence limits, 1.0 to 4.8%). Among the 31 patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment, there were no failures during chemotherapy and 4 (13%) subsequent relapses. SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/2904237/Five_year_follow_up_of_a_clinical_trial_of_three_6_month_regimens_of_chemotherapy_given_intermittently_in_the_continuation_phase_in_the_treatment_of_pulmonary_tuberculosis__Singapore_Tuberculosis_Service/British_Medical_Research_Council_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm/137.5.1147?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -